Plus Therapeutics (NASDAQ:CNSY) Raised to Hold at Zacks Research

Plus Therapeutics (NASDAQ:CNSY – Get Free Report) was upgraded by stock analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday, Zacks reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Plus Therapeutics in a research report on Monday, November 2nd. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce”.

Check Out Our Latest Analysis on CNSY

Plus Therapeutics Trading Up 23.3%

Shares of NASDAQ:CNSY traded up $0.18 during trading on Thursday, hitting $0.95. 8,046,110 shares of the company were exchanged, compared to its average volume of 1,810,277. Plus Therapeutics has a 52-week low of $0.43 and a 52-week high of $18.89. The firm has a market cap of $7.21 million, a P/E ratio of -0.28 and a beta of 1.49. The firm’s 50 day moving average is $1.70.

Plus Therapeutics (NASDAQ:CNSY – Get Free Report) last released its quarterly earnings results on Friday, November 13th. The company reported ($1.14) earnings per share for the quarter, missing the consensus estimate of ($0.98) by ($0.16). The firm had revenue of $0.72 million during the quarter. Plus Therapeutics had a negative return on equity of 394.17% and a negative net margin of 620.70%. On average, analysts anticipate that Plus Therapeutics will post -4.40 earnings per share for the current fiscal year.

Plus Therapeutics Company Profile

(Get Free Report)

Plus Therapeutics is a clinical-stage biopharmaceutical company developing targeted radiotherapeutics for cancers of the central nervous system. The company is based in Austin, Texas, and was formerly known as Cytori Therapeutics. Its lead investigational product, REYOBIQ (rhenium-186 obisbemeda), is designed to deliver radiation directly to tumors in the brain and central nervous system. The treatment is being studied for conditions including recurrent glioblastoma and leptomeningeal metastases.

See Also

Receive News & Ratings for Plus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Plus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.